Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148

Antiviral Therapy

Volumn 11, Issue 8, 2006, Pages 1081-1089

  Dubé, Michael P ^a   Wu, Julia W ^b   Aberg, Judith A ^c   Deeg, Mark A ^a   Alston Smith, Beverly L ^d   McGovern, Mark E ^e   Lee, Daniel ^f   Shriver, Sharon L ^g   Martinez, Ana I ^d   Greenwald, Martha ^a   Stein, James H ^h  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Kos Pharmaceuticals Inc   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; AMPRENAVIR; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; IBUPROFEN; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NAPROXEN; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NIACIN; TRIGLYCERIDES;

EID: 33845625228     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90:154-162.
2. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
3. Shor Posner G, Basit A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993; 94:515-519.
4. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO. Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS 2003; 17:189-194.
5. Stein JH. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis 2003; 45:293-304.
6. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
7. El-Sadr W, Reiss P, De Wit S, et al Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex, age, and lipid changes. 12th Conference on Retroviruses & Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Abstract 42.
8. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy. Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
9. Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005; 21:757-767.
10. Kahn SE, Beard JC, Schwartz MW, et al. Increased B-cell secretory capacity as a mechanism for islet cell adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989; 38:562-568.
11. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264:723-726.
12. Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med 1992; 93:102-104.
13. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994; 271:672-677.
14. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:298-302.
15. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Int Med 2005; 165:1179-84.
16. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-139.
17. Henry K, Kitch D, Dube M, et al. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS 2004; 18:2434-2437.
18. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
19. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
20. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Int Med 2005; 258:94-114.
21. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284:1263-1270.
22. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Int Med 2002; 162:1568-1576.
23. Gerber MT, Mondy KE, Yarasheski KE, et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004; 39:419-425.
24. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. In Handbook of Lipoprotein Testing, 3rd edn 2000; pp. 497-508. Edited by N Rifai, R Warnick & M Dominiczak. Washington, DC: AACC Press.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
26. Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987; 33:2153-2163.
27. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27:S5-S10.
28. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994; 11:286-292.
29. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22:1462-1470.
30. Dubé MP, Edmondson-Melançon H, Qian D, Aqeel R, Johnson DJ, Buchanan TA. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immune Defic Syndr 2001; 27:130-134.
31. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resis-tance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:F167-173.
32. Matthews DR, Hosker IP, Rudenski AS, Naylor DF, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
33. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-577.
34. Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004; 147:E18.
35. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolemia associated with protease inhibitor therapy. AIDS 2001; 15:1503-1508.
36. Doser N, Kübli S, Telenti A, et al. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS 2002; 16:1982-1983.
37. Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002; 16:2195-2200.
38. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002; 30:26-31.
39. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002; 22:1175-1180.
40. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23:847-852.
41. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003; 91:1432-1436.
42. Goldberg A, Alagona P, Jr., Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000; 85:1100-1105.